{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:35:19Z","timestamp":1792978519143,"version":"4.5.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000109"],"award-info":[{"award-number":["82000109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370143"],"award-info":[{"award-number":["82370143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["242300421509"],"award-info":[{"award-number":["242300421509"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01821-w","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T16:28:23Z","timestamp":1755966503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic options for extramedullary involvement in multiple myeloma"],"prefix":"10.1007","volume":"25","author":[{"given":"Junmei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"6","key":"1821_CR1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676\u201381.","journal-title":"Semin Oncol"},{"issue":"28","key":"1821_CR2","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez De Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805\u201312.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1821_CR3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360\u20134.","journal-title":"Haematologica"},{"issue":"3","key":"1821_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12(3):45.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1821_CR5","first-page":"1182","volume":"110","author":"K Xu","year":"2025","unstructured":"Xu K, Agbuduwe C, Kanellias N, Wilson W, McMillan A, Papanikolaou X, et al. Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single-center, real-world experience. Haematologica. 2025;110(5):1182\u20136.","journal-title":"Haematologica"},{"issue":"3","key":"1821_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk N, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194(3):496\u2013507.","journal-title":"Br J Haematol"},{"issue":"6","key":"1821_CR7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","volume":"54","author":"M Weinstock","year":"2013","unstructured":"Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54(6):1135\u201341.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1821_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","volume":"11","author":"J Caers","year":"2018","unstructured":"Caers J, Paiva B, Zamagni E, Leleu X, Blad\u00e9 J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1821_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1\u201320.","journal-title":"Leukemia"},{"issue":"10","key":"1821_CR10","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-024-05993-y","volume":"150","author":"D Zolnowski","year":"2024","unstructured":"Zolnowski D, Karp S, Warncke P, Zinn J, Pannach M, Herbst R, et al. Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma. J Cancer Res Clin Oncol. 2024;150(10): 482.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"1821_CR11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fern\u00e1ndez De Larrea","year":"2021","unstructured":"Fern\u00e1ndez De Larrea C, Kyle R, Rosi\u00f1ol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1821_CR12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906\u20138.","journal-title":"Leukemia"},{"issue":"9","key":"1821_CR13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"issue":"6","key":"1821_CR14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657\u201364.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1821_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","volume":"11","author":"R Bansal","year":"2021","unstructured":"Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021;11(9):161.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1821_CR16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Xie W, Laubach J, Ghobrial IM, O\u2019Donnell EK, Weinstock M, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843\u201350.","journal-title":"Br J Haematol"},{"issue":"1","key":"1821_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, Coriu D, Rosi\u00f1ol L, Ozet G, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;105(1):201\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"1821_CR18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10585-007-9108-4","volume":"25","author":"I Vande Broek","year":"2008","unstructured":"Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metas. 2008;25(4):325\u201334.","journal-title":"Clin Exp Metas"},{"key":"1821_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061430","author":"JJ Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s JJ, San-Miguel J, Paiva B. Biological characterization and clinical relevance of circulating tumor cells: opening the Pandora\u2019s box of multiple myeloma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14061430.","journal-title":"Cancers (Basel)"},{"key":"1821_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411259","author":"R McAvera","year":"2023","unstructured":"McAvera R, Quinn J, Murphy P, Glavey S. Genetic abnormalities in extramedullary multiple myeloma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241411259.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"1821_CR21","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","volume":"144","author":"M John","year":"2024","unstructured":"John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, et al. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024;144(20):2121\u201335.","journal-title":"Blood"},{"issue":"3","key":"1821_CR22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00277-014-2216-8","volume":"94","author":"SE Lee","year":"2015","unstructured":"Lee SE, Kim JH, Jeon YW, Yoon JH, Shin SH, Eom KS, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94(3):445\u201352.","journal-title":"Ann Hematol"},{"key":"1821_CR23","doi-asserted-by":"crossref","unstructured":"Ho M; Paruzzo L; Minehart J; Nabar N; Noll JH; Luo T, et al. Extramedullary Multiple Myeloma: Challenges and Opportunities. Current oncology Toronto Ont. 2025;32(3).","DOI":"10.3390\/curroncol32030182"},{"issue":"10","key":"1821_CR24","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","volume":"105","author":"A Gulla","year":"2020","unstructured":"Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020;105(10):2358\u201367.","journal-title":"Haematologica"},{"issue":"1","key":"1821_CR25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41408-024-01190-9","volume":"14","author":"R Nakamoto-Matsubara","year":"2024","unstructured":"Nakamoto-Matsubara R, Nardi V, Horick N, Fukushima T, Han RS, Shome R, et al. Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer J. 2024;14(1):224.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1821_CR26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-024-01208-2","volume":"15","author":"N Bingham","year":"2025","unstructured":"Bingham N, Shah J, Wong D, Lim SL, Bergin K, Kalff A, et al. Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma. Blood Cancer J. 2025;15(1):5.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1821_CR27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38(6):1323\u201333.","journal-title":"Leukemia"},{"issue":"7","key":"1821_CR28","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","volume":"109","author":"Y Alsayed","year":"2007","unstructured":"Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708\u201317.","journal-title":"Blood"},{"issue":"4","key":"1821_CR29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","volume":"12","author":"AM Roccaro","year":"2015","unstructured":"Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015;12(4):622\u201335.","journal-title":"Cell Rep"},{"issue":"2","key":"1821_CR30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2002.03258.x","volume":"116","author":"IM Dahl","year":"2002","unstructured":"Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116(2):273\u20137.","journal-title":"Br J Haematol"},{"issue":"1","key":"1821_CR31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03748-0","volume":"12","author":"D Hathi","year":"2022","unstructured":"Hathi D, Chanswangphuwana C, Cho N, Fontana F, Maji D, Ritchey J, et al. Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. Sci Rep. 2022;12(1): 30.","journal-title":"Sci Rep"},{"issue":"5","key":"1821_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2462.x","volume":"76","author":"R Laura","year":"2006","unstructured":"Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blad\u00e9 J, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405\u20138.","journal-title":"Eur J Haematol"},{"issue":"4","key":"1821_CR33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","volume":"92","author":"D Dingli","year":"2017","unstructured":"Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. Therapy for relapsed multiple myeloma: guidelines from the mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017;92(4):578\u201398.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1821_CR34","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07732-1","volume":"21","author":"J Minarik","year":"2021","unstructured":"Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, et al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021;21(1): 73.","journal-title":"BMC Cancer"},{"issue":"1","key":"1821_CR35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13799","volume":"172","author":"E Muchtar","year":"2016","unstructured":"Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol. 2016;172(1):89\u201396.","journal-title":"Br J Haematol"},{"issue":"11","key":"1821_CR36","first-page":"3681","volume":"109","author":"JH Lee","year":"2024","unstructured":"Lee JH, Choi J, Min CK, Park SS, Jo JC, Lee YJ, et al. Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study. Haematologica. 2024;109(11):3681\u201392.","journal-title":"Haematologica"},{"issue":"2","key":"1821_CR37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392(2):138\u201349.","journal-title":"N Engl J Med"},{"key":"1821_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041035","author":"X Zhou","year":"2020","unstructured":"Zhou X, Fl\u00fcchter P, Nickel K, Meckel K, Messerschmidt J, B\u00f6ckle D, et al. Carfilzomib based treatment strategies in the management of relapsed\/refractory multiple myeloma with extramedullary disease. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12041035.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1821_CR39","first-page":"88","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Ji J, Lu H, Li J, Qu X. Pomalidomide-based therapy for extramedullary multiple myeloma. Hematology (Amsterdam, Netherlands). 2022;27(1):88\u201394.","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"1821_CR40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-016-0040-7","volume":"5","author":"T Ichinohe","year":"2015","unstructured":"Ichinohe T, Kuroda Y, Okamoto S, Matsue K, Iida S, Sunami K, et al. A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol. 2015;5:11.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1821_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37\u201344.","journal-title":"Blood"},{"issue":"10027","key":"1821_CR42","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet (London, England). 2016;387(10027):1551\u201360.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1821_CR43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","volume":"36","author":"T Jelinek","year":"2022","unstructured":"Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36(1):288\u201391.","journal-title":"Leukemia"},{"issue":"1","key":"1821_CR44","volume":"15","author":"JM Byun","year":"2022","unstructured":"Byun JM, Min CK, Kim K, Bang SM, Lee JJ, Kim JS, et al. Phase II trial of daratumumab with DCEP in relapsed\/refractory multiple myeloma patients with extramedullary disease. J Hematol Oncol. 2022;15(1): 150.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"1821_CR45","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"issue":"7","key":"1821_CR46","first-page":"832","volume":"89","author":"L Rosi\u00f1ol","year":"2004","unstructured":"Rosi\u00f1ol L, Cibeira MT, Blad\u00e9 J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832\u20136.","journal-title":"Haematologica"},{"issue":"2","key":"1821_CR47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1046\/j.1365-2141.2001.02765.x","volume":"113","author":"J Blad\u00e9","year":"2001","unstructured":"Blad\u00e9 J, Perales M, Rosi\u00f1ol L, Tuset M, Montoto S, Esteve J, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol. 2001;113(2):422\u20134.","journal-title":"Br J Haematol"},{"issue":"11","key":"1821_CR48","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1080\/10428190410001733772","volume":"45","author":"A Anagnostopoulos","year":"2004","unstructured":"Anagnostopoulos A, Gika D, Hamilos G, Zervas K, Zomas A, Pouli A, et al. Treatment of relapsed\/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma. 2004;45(11):2275\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"1821_CR49","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.leukres.2008.09.018","volume":"33","author":"AM Oliveira","year":"2009","unstructured":"Oliveira AM, Maria DA, Metzger M, Linardi C, Giorgi RR, Moura F, et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res. 2009;33(7):970\u20133.","journal-title":"Leuk Res"},{"issue":"1","key":"1821_CR50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdl129","volume":"18","author":"P Raanani","year":"2007","unstructured":"Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies for hematological malignancies\u2013is the association real? Ann Oncol. 2007;18(1):7\u201312.","journal-title":"Ann Oncol"},{"issue":"3","key":"1821_CR51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0609.2011.01644.x","volume":"87","author":"JM Calvo-Villas","year":"2011","unstructured":"Calvo-Villas JM, Alegre A, Calle C, Hern\u00e1ndez MT, Garc\u00eda-S\u00e1nchez R, Ram\u00edrez G. Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol. 2011;87(3):281\u20134.","journal-title":"Eur J Haematol"},{"issue":"4","key":"1821_CR52","first-page":"1297","volume":"109","author":"L Notarfranchi","year":"2024","unstructured":"Notarfranchi L, Accardi F, Mancini C, Martella E, Bonomini S, Segreto R, et al. CD38 expression by plasma cells in extramedullary multiple myeloma. Haematologica. 2024;109(4):1297\u2013300.","journal-title":"Haematologica"},{"issue":"9","key":"1821_CR53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1821_CR54","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00277-021-04447-6","volume":"100","author":"S Danhof","year":"2021","unstructured":"Danhof S, Rasche L, Mottok A, Steinm\u00fcller T, Zhou X, Schreder M, et al. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Ann Hematol. 2021;100(6):1537\u201346.","journal-title":"Ann Hematol"},{"issue":"1","key":"1821_CR55","doi-asserted-by":"crossref","first-page":"28557","DOI":"10.1038\/s41598-024-79537-2","volume":"14","author":"J Yin","year":"2024","unstructured":"Yin J, Zhou X, Li X, Yuan C, Chu X, Hao L, et al. Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease. Sci Rep. 2024;14(1):28557.","journal-title":"Sci Rep"},{"issue":"8","key":"1821_CR56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"1821_CR57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"D Dima","year":"2024","unstructured":"Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J. 2024;14(1):90.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1821_CR58","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17(1): 42.","journal-title":"J Hematol Oncol"},{"key":"1821_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030525","author":"C Besliu","year":"2025","unstructured":"Besliu C, Tanase AD, Rotaru I, Espinoza J, Vidal L, Poelman M, et al. The evolving landscape in multiple myeloma: from risk stratification to T cell-directed advanced therapies. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17030525.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1821_CR60","volume":"6","author":"J Zhao","year":"2024","unstructured":"Zhao J, Yang H, Ge J, Li L, Yao Q, He S, et al. Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia\/lymphoma with extramedullary disease. Blood Sci (Baltimore, Md). 2024;6(2): e00184.","journal-title":"Blood Sci (Baltimore, Md)"},{"issue":"1","key":"1821_CR61","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12967-023-04655-w","volume":"21","author":"D Wang","year":"2023","unstructured":"Wang D, Fu H, Que Y, Ruan H, Xu M, Long X, et al. A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma. J Transl Med. 2023;21(1):812.","journal-title":"J Transl Med"},{"issue":"14","key":"1821_CR62","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(14):1665\u201375.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1821_CR63","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk N, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141(3):219\u201330.","journal-title":"Blood"},{"issue":"10297","key":"1821_CR64","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet (London, England). 2021;398(10297):314\u201324.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"1821_CR65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"20","key":"1821_CR66","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol. 2022;40(20):2246\u201356.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1821_CR67","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","volume":"27","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R, et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin Cancer Res. 2021;27(23):6384\u201392.","journal-title":"Clin Cancer Res"},{"key":"1821_CR68","volume":"12","author":"Y Que","year":"2021","unstructured":"Que Y, Xu M, Xu Y, Almeida VDF, Zhu L, Wang Z, et al. Anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease: a single center analysis of two clinical trials. Front Immunol. 2021;12: 755866.","journal-title":"Front Immunol"},{"issue":"18","key":"1821_CR69","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"19","key":"1821_CR70","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci USA. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1821_CR71","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321.","journal-title":"J Clin Invest"},{"issue":"21","key":"1821_CR72","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood. 2021;137(21):2890\u2013901.","journal-title":"Blood"},{"issue":"3","key":"1821_CR73","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11(3): e346.","journal-title":"Clin Transl Med"},{"issue":"2","key":"1821_CR74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hon.2958","volume":"40","author":"W Li","year":"2022","unstructured":"Li W, Liu M, Yuan T, Yan L, Cui R, Deng Q. Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease. Hematol Oncol. 2022;40(2):223\u201332.","journal-title":"Hematol Oncol"},{"issue":"17","key":"1821_CR75","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1158\/1078-0432.CCR-24-0414","volume":"30","author":"D Chen","year":"2024","unstructured":"Chen D, Zhu Y, Chen Z, Jiang S, He H, Qiang W, et al. A 5-year follow-up clinical study of the b-cell maturation antigen chimeric antigen receptor t-cell therapy HDS269B in patients with relapsed or refractory multiple myeloma. Clin Cancer Res. 2024;30(17):3747\u201356.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1821_CR76","first-page":"1514","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024;109(5):1514\u201324.","journal-title":"Haematologica"},{"key":"1821_CR77","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of humanized Anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol. 2021;12: 720571.","journal-title":"Front Immunol"},{"key":"1821_CR78","doi-asserted-by":"crossref","unstructured":"Pan D; Mouhieddine TH; Sheng T; Fu W; Moshier E; Richter J, et al. Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma. Bone marrow transplantation. 2025.","DOI":"10.1038\/s41409-025-02593-3"},{"issue":"14","key":"1821_CR79","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41(14):2583\u201393.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1821_CR80","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10(2):e107\u201316.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1821_CR81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W, Liao D, Xie W, Wei Q, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2024;38(1):149\u201359.","journal-title":"Leukemia"},{"issue":"1","key":"1821_CR82","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1): 161.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"1821_CR83","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","volume":"10","author":"W Qiang","year":"2024","unstructured":"Qiang W, Lu J, Jia Y, Liu J, Liu J, He H, et al. B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma. JAMA Oncol. 2024;10(9):1259\u201363.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1821_CR84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","volume":"41","author":"Y Tang","year":"2022","unstructured":"Tang Y, Yin H, Zhao X, Jin D, Liang Y, Xiong T, et al. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exper Clin Cancer Res\u202f: CR. 2022;41(1):2.","journal-title":"J Exper Clin Cancer Res : CR"},{"issue":"12","key":"1821_CR85","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/ajh.27469","volume":"99","author":"Y Qi","year":"2024","unstructured":"Qi Y, Li H, Qi K, Zhu F, Cheng H, Chen W, et al. Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy. Am J Hematol. 2024;99(12):2286\u201395.","journal-title":"Am J Hematol"},{"issue":"10","key":"1821_CR86","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","volume":"11","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, et al. Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol. 2024;11(10):e751\u201360.","journal-title":"Lancet Haematol"},{"issue":"24","key":"1821_CR87","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"1821_CR88","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"2","key":"1821_CR89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38(2):365\u201371.","journal-title":"Leukemia"},{"issue":"1","key":"1821_CR90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14(1):35.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1821_CR91","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"1","key":"1821_CR92","volume":"131","author":"Z Cai","year":"2025","unstructured":"Cai Z, Xia Z, He AL, Dong YJ, Wang Y, Liao A, et al. Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1. Cancer. 2025;131(1): e35665.","journal-title":"Cancer"},{"issue":"23","key":"1821_CR93","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024;144(23):2375\u201388.","journal-title":"Blood"},{"issue":"4","key":"1821_CR94","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70114","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, et al. A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma. HemaSphere. 2025;9(4): e70114.","journal-title":"HemaSphere"},{"issue":"4","key":"1821_CR95","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 2025;12(4):e269\u201381.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1821_CR96","volume":"14","author":"D Jiang","year":"2023","unstructured":"Jiang D, Huang H, Qin H, Tang K, Shi X, Zhu T, et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun. 2023;14(1): 3642.","journal-title":"Nat Commun"},{"issue":"1","key":"1821_CR97","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-025-01226-8","volume":"15","author":"R Dileo","year":"2025","unstructured":"Dileo R, Mewawalla P, Babu K, Yin Y, Strouse C, Chen E, et al. A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma. Blood Cancer J. 2025;15(1): 34.","journal-title":"Blood Cancer J"},{"key":"1821_CR98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/BLCTT.S490021","volume":"14","author":"AA Almodovar Diaz","year":"2024","unstructured":"Almodovar Diaz AA, Alouch SS, Chawla Y, Gonsalves WI. The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: a comprehensive review. Blood Lymphat Cancer Targets Ther. 2024;14:71\u201387.","journal-title":"Blood Lymphat Cancer Targets Ther"},{"issue":"11","key":"1821_CR99","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","volume":"25","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of the european society for blood and marrow transplantation. Biol Blood Marrow trans. 2019;25(11):2134\u201342.","journal-title":"Biol Blood Marrow trans"},{"issue":"4","key":"1821_CR100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","volume":"162","author":"CI Chen","year":"2013","unstructured":"Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda VH, et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013;162(4):483\u20138.","journal-title":"Br J Haematol"},{"issue":"6","key":"1821_CR101","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.24351","volume":"91","author":"A Jurczyszyn","year":"2016","unstructured":"Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, et al. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91(6):575\u201380.","journal-title":"Am J Hematol"},{"issue":"12","key":"1821_CR102","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00277-015-2484-y","volume":"94","author":"E Katodritou","year":"2015","unstructured":"Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, et al. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek myeloma study group experience. Ann Hematol. 2015;94(12):2033\u201342.","journal-title":"Ann Hematol"},{"issue":"1","key":"1821_CR103","volume":"4","author":"LG Fernandez 3rd","year":"2022","unstructured":"Fernandez LG 3rd, Oyon DE, Gondi V, Grimm S, Khan OH. Secondary CNS myeloma with remission after systemic CNS-penetrating agents. Neuro-oncol Adv. 2022;4(1): vdac106.","journal-title":"Neuro-oncol Adv"},{"issue":"4","key":"1821_CR104","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3109\/10428194.2012.718343","volume":"54","author":"A Mussetti","year":"2013","unstructured":"Mussetti A, Dalto S, Montefusco V. Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma. 2013;54(4):864\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1821_CR105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bjh.14498","volume":"177","author":"A Badros","year":"2017","unstructured":"Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, et al. Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017;177(2):221\u20135.","journal-title":"Br J Haematol"},{"issue":"5","key":"1821_CR106","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/neuonc\/nou303","volume":"17","author":"AL Green","year":"2015","unstructured":"Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, et al. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro-oncol. 2015;17(5):697\u2013707.","journal-title":"Neuro-oncol"},{"issue":"2","key":"1821_CR107","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.3324\/haematol.2017.181636","volume":"103","author":"S Bobillo","year":"2018","unstructured":"Bobillo S, Abrisqueta P, Carpio C, Raheja P, Castellv\u00ed J, Crespo M, et al. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 2018;103(2):e92\u20133.","journal-title":"Haematologica"},{"issue":"10","key":"1821_CR108","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajh.27425","volume":"99","author":"E Katodritou","year":"2024","unstructured":"Katodritou E, Dalampira D, Delimpasi S, Ntanasis-Stathopoulos I, Karaolidou F, Gkioka AI, et al. Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group. Am J Hematol. 2024;99(10):1897\u2013905.","journal-title":"Am J Hematol"},{"issue":"4","key":"1821_CR109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<228::AID-AJH5>3.0.CO;2-3","volume":"62","author":"SL Petersen","year":"1999","unstructured":"Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol. 1999;62(4):228\u201333.","journal-title":"Am J Hematol"},{"issue":"1","key":"1821_CR110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1871524914999140818111514","volume":"14","author":"A Gozzetti","year":"2014","unstructured":"Gozzetti A, Cerase A. Novel agents in CNS myeloma treatment. Cent Nerv Syst Agents Med Chem. 2014;14(1):23\u20137.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"1821_CR111","doi-asserted-by":"crossref","first-page":"1610276","DOI":"10.3389\/pore.2022.1610276","volume":"28","author":"VR Szita","year":"2022","unstructured":"Szita VR, Mikala G, Kozma A, F\u00e1bi\u00e1n J, Hardi A, Alizadeh H, et al. Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers. Pathol Oncol Res\u202f: POR. 2022;28:1610276.","journal-title":"Pathol Oncol Res : POR"},{"issue":"1","key":"1821_CR112","first-page":"25","volume":"45","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zu C, Teng X, Yang L, Zhang M, Hong R, et al. BCMA CAR-T therapy is safe and effective for refractory\/relapsed multiple myeloma with central nervous system involvement. J Immunother Hagerstown Md 1997. 2022;45(1):25\u201334.","journal-title":"J Immunother Hagerstown Md 1997."},{"issue":"5","key":"1821_CR113","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","volume":"9","author":"MR Gaballa","year":"2025","unstructured":"Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, et al. BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv. 2025;9(5):1171\u201380.","journal-title":"Blood Adv"},{"issue":"7","key":"1821_CR114","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","volume":"105","author":"PA Egan","year":"2020","unstructured":"Egan PA, Elder PT, Deighan WI, O\u2019Connor SJM, Alexander HD. Multiple myeloma with central nervous system relapse. Haematologica. 2020;105(7):1780\u201390.","journal-title":"Haematologica"},{"key":"1821_CR115","doi-asserted-by":"crossref","first-page":"1511261","DOI":"10.3389\/fonc.2025.1511261","volume":"15","author":"KR Tringale","year":"2025","unstructured":"Tringale KR, Imber BS, Cederquist GY, Yahalom J, Moore ZR, Hoppe RT, et al. Urgent and emergent radiotherapy for hematologic malignancies of the central nervous system: a review of the literature and practical approach. Front Oncol. 2025;15:1511261.","journal-title":"Front Oncol"},{"key":"1821_CR116","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2023-190019","volume":"142","author":"CTR Vegivinti","year":"2023","unstructured":"Vegivinti CTR, Lawrence Alexander Santhi J, Liu L, Keesari PR, Thakur R, Hammami MB, et al. Efficacy of bispecific antibodies Vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: a systematic review and meta-analysis. Blood. 2023;142:1994\u20131994.","journal-title":"Blood"},{"issue":"1","key":"1821_CR117","volume":"14","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, et al. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14(1): 122.","journal-title":"Blood Cancer J"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01821-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:32Z","timestamp":1764917312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01821-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01821-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is a literature review and does not require the informed consent of patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"301"}}